CRVO — CervoMed Cashflow Statement
0.000.00%
- $89.20m
- $50.28m
- $9.74m
- 25
- 15
- 37
- 14
Annual cashflow statement for CervoMed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.2 | -24.1 | -15.6 | -2.17 | -16.3 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.736 | 9.59 | 0.719 | -5.02 | 0.201 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.47 | 0.356 | -0.097 | -0.261 | -0.441 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -13.6 | -14.5 | -15 | -7.45 | -16.5 |
Other Investing Cash Flow Items | — | 0.004 | -12.2 | — | -28.7 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | — | 0.004 | -12.2 | — | -28.7 |
Financing Cash Flow Items | -0.982 | 0 | — | 10.3 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 17.9 | 33.3 | 0.005 | 11.1 | 46.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 4.34 | 18.8 | -27.2 | 3.7 | 1.21 |